Novolog (Pharm-Up 1966) Ltd (NVLG.TA)

ILA 147.4

(3.08%)

Operating Expenses Summary of Novolog (Pharm-Up 1966) Ltd

Novolog (Pharm-Up 1966) Ltd's latest annual operating expenses in 2023 was 171.11 Million ILS , up 21.62% from previous year.
Novolog (Pharm-Up 1966) Ltd's latest quarterly operating expenses in 2024 Q2 was 26.44 Million ILS , down -4.5% from previous quarter.
Novolog (Pharm-Up 1966) Ltd reported a annual operating expenses of 97.63 Million ILS in annual operating expenses 2022, up 20.4% from previous year.
Novolog (Pharm-Up 1966) Ltd reported a annual operating expenses of 81.09 Million ILS in annual operating expenses 2021, up 8.85% from previous year.
Novolog (Pharm-Up 1966) Ltd reported a quarterly operating expenses of 26.44 Million ILS for 2024 Q2, down -4.5% from previous quarter.
Novolog (Pharm-Up 1966) Ltd reported a quarterly operating expenses of 118.74 Million ILS for 2023 FY, up 21.62% from previous quarter.

Annual Operating Expenses Chart of Novolog (Pharm-Up 1966) Ltd (2023 - 2013)

Historical Annual Operating Expenses of Novolog (Pharm-Up 1966) Ltd (2023 - 2013)

Year	Operating Expenses	Operating Expenses Growth
2023	171.11 Million ILS	21.62%
2022	97.63 Million ILS	20.4%
2021	81.09 Million ILS	8.85%
2020	74.5 Million ILS	14.64%
2019	64.98 Million ILS	29.67%
2018	50.11 Million ILS	23.96%
2017	40.43 Million ILS	27.03%
2016	31.82 Million ILS	8.42%
2015	29.35 Million ILS	2.31%
2014	28.69 Million ILS	5.15%
2013	27.28 Million ILS	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	27.57 Million ILS	-14.88%
2024 Q2	26.44 Million ILS	-4.5%
2023 FY	118.74 Million ILS	21.62%
2023 Q1	26.56 Million ILS	13.54%
2023 Q4	32.39 Million ILS	4.25%
2023 Q2	28.7 Million ILS	8.06%
2023 Q3	31.07 Million ILS	8.24%
2022 Q1	24.67 Million ILS	2.65%
2022 FY	97.63 Million ILS	20.4%
2022 Q4	23.39 Million ILS	-7.17%
2022 Q3	25.2 Million ILS	3.48%
2022 Q2	24.35 Million ILS	-1.27%
2021 Q3	18.67 Million ILS	-1.35%
2021 FY	81.09 Million ILS	8.85%
2021 Q2	18.93 Million ILS	-2.66%
2021 Q1	19.45 Million ILS	-17.96%
2021 Q4	24.03 Million ILS	28.7%
2020 Q3	17.92 Million ILS	8.91%
2020 Q1	16.42 Million ILS	-26.23%
2020 Q2	16.45 Million ILS	0.2%
2020 FY	74.5 Million ILS	14.64%
2020 Q4	23.7 Million ILS	32.29%
2019 Q2	14.44 Million ILS	7.53%
2019 FY	64.98 Million ILS	29.67%
2019 Q4	22.26 Million ILS	49.89%
2019 Q3	14.85 Million ILS	2.82%
2019 Q1	13.43 Million ILS	-3.71%
2018 Q1	12.01 Million ILS	-11.0%
2018 FY	50.11 Million ILS	23.96%
2018 Q4	13.94 Million ILS	15.63%
2018 Q3	12.06 Million ILS	-0.24%
2018 Q2	12.09 Million ILS	0.66%
2017 Q2	8.54 Million ILS	-4.76%
2017 Q3	9.41 Million ILS	10.25%
2017 FY	40.43 Million ILS	27.03%
2017 Q4	13.49 Million ILS	43.31%
2017 Q1	8.97 Million ILS	-1.72%
2016 Q1	7.12 Million ILS	-29.24%
2016 Q4	9.12 Million ILS	16.92%
2016 FY	31.82 Million ILS	8.42%
2016 Q3	7.8 Million ILS	0.23%
2016 Q2	7.78 Million ILS	9.37%
2015 FY	29.35 Million ILS	2.31%
2015 Q3	6.56 Million ILS	0.0%
2015 Q4	10.06 Million ILS	53.27%
2014 FY	28.69 Million ILS	5.15%
2013 FY	27.28 Million ILS	0.0%

Peer Operating Expenses Comparison of Novolog (Pharm-Up 1966) Ltd

Name	Operating Expenses	Operating Expenses Difference